Key Takeaway
If you have been following the tirzepatide supply situation, you know it has been a roller coaster. This tirzepatide shortage status 2026 resource covers the important information you need to make informed decisions. Shortages disrupted access for millions of patients.
If you have been following the tirzepatide supply situation, you know it has been a roller coaster. This tirzepatide shortage status 2026 resource covers the important information you need to make informed decisions. Shortages disrupted access for millions of patients. Pharmacies couldn't fill prescriptions. Waiting lists stretched for months. But the tirzepatide shortage status in 2026 has shifted significantly. Here is what you need to know about current availability, what has changed, and how to make sure you can access the medication you need.
Key Takeaways: - Current Supply Status: Where Things Stand - Learn how the shortage affected compounding and what has changed - Learn how to secure your supply: practical tips - Understand what to do if you can't get your medication
Current Supply Status: Where Things Stand
The FDA officially removed tirzepatide from its drug shortage list in October 2024. This was a major milestone. During the shortage period, which began in late 2022 and lasted nearly two years, patients faced unpredictable delays and frequent pharmacy substitutions.
Since coming off the shortage list, brand-name tirzepatide availability has improved substantially. Single-dose vials are now available alongside the auto-injector pens, giving pharmacies more flexibility in filling prescriptions. The manufacturer has increased production capacity and expanded its supply chain to meet surging demand.
But "off the shortage list" doesn't mean every pharmacy has every dose in stock at all times. Some patients still report intermittent delays, particularly at smaller pharmacies or for specific dose strengths. The most commonly available doses are the starter doses of 2.5 mg and 5 mg. Higher doses like 12.5 mg and 15 mg may still occasionally require a short wait at some locations.
The supply situation also varies by region. Urban areas with more pharmacy options generally have better availability than rural communities. If you're experiencing delays, ask your pharmacy to check inventory at nearby locations within the same chain.
For a complete look at the medication itself, see our .
"Compounding pharmacies serve a critical role in healthcare, but patients need to understand the difference between a properly regulated 503B facility and an unregulated operation. Ask about PCAB accreditation and third-party testing.") Dr. Scott Brunner, PharmD, Alliance for Pharmacy Compounding
How the Shortage Affected Compounding and What Has Changed
The tirzepatide shortage had a significant impact on the compounding pharmacy environment. Under FDA regulations, 503A compounding pharmacies can prepare compounded versions of medications that are on the FDA drug shortage list. During the shortage, many patients turned to compounded tirzepatide as a reliable and more affordable alternative. For a complete cost breakdown, see our compare tirzepatide pharmacies.
View data table
| Category | Mean Body Weight Loss (%) | Detail |
|---|---|---|
| Tirzepatide | 22 | ~22% body weight at 72 wks |
| Semaglutide | 15 | ~15% body weight at 68 wks |
| Liraglutide | 8 | ~8% body weight at 56 wks |
| Retatrutide | 24 | ~24% in Phase 2 trial |
When the FDA removed tirzepatide from the shortage list in October 2024, questions arose about the future of compounded tirzepatide. The market has been evolving, with ongoing discussions about how compounding pharmacies can continue to serve patients.
As of early 2026, the situation remains dynamic. Several factors influence compounded tirzepatide availability:
- State-level regulations vary in how they interpret federal compounding rules. Some states have their own frameworks that allow compounding pharmacies to continue preparing certain medications.
- 503A vs 503B pharmacies operate under different regulatory frameworks. 503A pharmacies compound based on individual patient prescriptions, while 503B outsourcing facilities can produce larger batches.
- Patient access advocacy continues to push for broader access to affordable compounded alternatives, particularly for patients who can't afford brand-name pricing.
Patient Perspective: "I switched from semaglutide to tirzepatide after plateauing at 4 months. Within 6 weeks on tirzepatide, the scale started moving again. The dual mechanism really does seem to work differently for some people.", David L., 44, FormBlends patient (name changed for privacy)
FormBlends works with licensed providers and pharmacies who stay current with all regulatory requirements. Your provider can advise you on the most up-to-date options available in your state. .
Free Download: Tirzepatide Dose Escalation Calendar Plan your tirzepatide protocol with confidence using our printable dose calendar. Track your doses, injection sites, and progress week by week. Get yours free, we'll email it to you instantly. [Email Input] [Download Button]
How to Secure Your Supply: Practical Tips
Whether you use brand-name or compounded tirzepatide, a few strategies can help you avoid gaps in your treatment.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Plan ahead on refills. Don't wait until your last dose to request a refill. Aim to refill at least 7-10 days before you run out. This gives your pharmacy time to order stock if it isn't on the shelf. If you use a mail-order pharmacy, build in even more lead time since shipping adds a few days.
Stay in communication with your provider. If your pharmacy can't fill your prescription at your current dose, your provider may be able to adjust your prescription temporarily. For example, two smaller-dose vials might be combined to match your prescribed dose. Never make dosing adjustments on your own.
Use specialty pharmacies. Specialty pharmacies that focus on injectable medications often have more reliable stock than general retail pharmacies. They also tend to have better relationships with manufacturers and distributors, which can mean faster restocking.
Consider telehealth platforms. Platforms like FormBlends coordinate the prescription and pharmacy fulfillment process, which can reduce the chance of supply gaps. When your provider and pharmacy are connected through the same system, refills happen more smoothly.
Keep records of your protocol. If you ever need to switch pharmacies or providers, having a clear record of your dose history, titration schedule, and injection dates makes the transition straightforward. The can help you track all of this in one place.
What to Do If You Can't Get Your Medication
If you face a gap in your tirzepatide supply, don't panic. Here is what to know.
Short gaps (1-2 weeks) are manageable. Missing one or two doses isn't ideal, but it won't erase your progress. Your appetite may increase slightly, and you might notice some mild return of cravings. Resume your normal dose as soon as your medication is available. You typically don't need to restart the titration process for a gap this short.
Longer gaps (3+ weeks) may require retitration. If you're off tirzepatide for three weeks or more, your provider may recommend restarting at a lower dose and titrating back up. This helps minimize gastrointestinal side effects that can occur when jumping back to a higher dose after a break.
Don't substitute without provider guidance. Switching between tirzepatide and another GLP-1 medication requires medical supervision. The dosing, mechanisms, and side effect profiles are different. Your provider can help you work through any necessary transitions safely.
Report shortages. If your pharmacy reports a shortage, you can also report it directly to the FDA through their Drug Shortage Database. Patient reports help the FDA monitor supply chain issues and work with manufacturers to resolve them.
For guidance on how tirzepatide compares to other options that might be available, see our .
Frequently Asked Questions
Is tirzepatide still on the FDA shortage list in 2026?
No. The FDA removed tirzepatide from its drug shortage list in October 2024. Supply of the brand-name product has improved significantly since then, though some patients may still experience occasional delays at specific pharmacies or for certain dose strengths.
Can I still get compounded tirzepatide?
The availability of compounded tirzepatide depends on current federal and state regulations. The market has been evolving since tirzepatide came off the shortage list. FormBlends providers stay current with all regulatory requirements and can advise you on the options available in your state.
What should I do if my pharmacy can't fill my tirzepatide prescription?
Contact your provider immediately. They may be able to send your prescription to a different pharmacy, adjust the formulation, or explore alternative fulfillment options. Don't skip doses or adjust your dose on your own. Planning refills 7-10 days in advance also helps prevent supply gaps.
Will the tirzepatide shortage come back?
Predicting drug shortages is difficult, but the manufacturer has invested significantly in expanding production capacity. Demand for tirzepatide remains high, which always creates some risk of supply strain. The best strategy is to plan ahead on refills and maintain a relationship with a provider who can pivot quickly if needed.
Is brand-name tirzepatide available in all dose strengths?
Most dose strengths are now available, including 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Single-dose vials and auto-injector pens are both on the market. But specific dose availability can vary by pharmacy location. Higher doses may occasionally be on backorder at some pharmacies.
Your Personalized Plan Is Waiting
No two patients are the same, and your protocol shouldn't be either. FormBlends providers create customized treatment plans based on your health profile, goals, and preferences.
Medical References
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. [PubMed | ClinicalTrials.gov | DOI]
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide with intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3). Nat Med. 2024. [PubMed | ClinicalTrials.gov | DOI]
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4). JAMA. 2024;331(1):38-48. [PubMed | ClinicalTrials.gov | DOI]
Sources &. References
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2[1] (Garvey et al., Lancet, 2023)). Lancet. 2023;402(10402):613-626. Doi:10.1016/S0140-6736(23)01200-X
- Wadden TA, Chao AM, Engel S, et al. Tirzepatide after intensive lifestyle intervention in adults with overweight or obesity (SURMOUNT-3[2] (Wadden et al., Nat Med, 2023)). Nat Med. 2023. Doi:10.1038/s41591-023-02597-w
- Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity (SURMOUNT-4[3] (Aronne et al., JAMA, 2024)). JAMA. 2024;331(1):38-48. Doi:10.1001/jama.2023.24945
- Malhotra A, Grunstein RR, Fietze I, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391:1193-1205. Doi:10.1056/NEJMoa2404881
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. Doi:10.1056/NEJMoa2032183
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. Doi:10.1056/NEJMoa2206038
- Nauck MA, Meier JJ. Management of endocrine disease: Are all GLP-1 agonists equal in the treatment of type 2 diabetes? Eur J Endocrinol. 2019;181(6):R211-R234. Doi:10.1530/EJE-19-0566
- Stierman B, Afful J, Carroll MD, et al. National Health and Nutrition Examination Survey 2017-March 2020 Prepandemic Data Files. NCHS Data Brief. No. 492. CDC/NCHS. 2023.
- Sumithran P, Prendergast LA, Delbridge E, et al. Long-Term Persistence of Hormonal Adaptations to Weight Loss. N Engl J Med. 2011;365(17):1597-1604. Doi:10.1056/NEJMoa1105816
This content is provided for informational and educational purposes only. It isn't a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of a licensed healthcare provider with any questions about a medical condition or treatment plan.
Last updated: 2026-03-24